Polireddy Karunesh, Crepeau Rebecca L, Matar Abraham J
Emory University School of Medicine, Atlanta, GA, United States.
Department of Surgery, Emory University School of Medicine, Atlanta, GA, United States.
Front Med (Lausanne). 2023 Jun 30;10:1061342. doi: 10.3389/fmed.2023.1061342. eCollection 2023.
The incidence of end stage renal disease (ESRD) in the United States (US) is increasing each year. The lone curative treatment for ESRD remains kidney transplantation. Despite the demonstrated medical and economic benefits, living donor kidney transplantation (LDKT) only accounts for a small number of kidney transplantations each year. Direct and indirect costs exist that disincentivize potential living kidney donors from coming forward, such as the cost of travel and lodging, risk of death, potential loss of income due to an extended recovery time, and the inability to donate to a relative in the future if needed. Herein, we advocate for policy changes that make living kidney donation (LKD) a financially neutral process thereby incentivizing increased LDKT and mitigating the kidney donor shortage.
美国终末期肾病（ESRD）的发病率逐年上升。ESRD唯一的治愈性治疗方法仍然是肾移植。尽管肾移植已证明具有医学和经济效益，但活体供肾移植（LDKT）每年在肾移植中所占比例仍较小。存在直接和间接成本，这些成本阻碍了潜在的活体肾供体挺身而出，例如差旅费、住宿费、死亡风险、因恢复时间延长可能导致的收入损失，以及未来如有需要无法捐肾给亲属。在此，我们主张政策变革，使活体肾捐赠（LKD）成为一个财务中性的过程，从而激励增加LDKT并缓解肾供体短缺问题。
